Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/05/2020 08/06/2020 08/07/2020 08/10/2020 08/11/2020 Date
1573.2(c) 1550(c) 1555.2(c) 1553.2(c) 1576(c) Last
5 324 205 4 691 863 4 168 560 3 771 920 4 860 696 Volume
+0.01% -1.47% +0.34% -0.13% +1.47% Change
More quotes
Financials
Sales 2020 35 199 M 45 935 M 45 935 M
Net income 2020 4 615 M 6 022 M 6 022 M
Net Debt 2020 23 138 M 30 196 M 30 196 M
P/E ratio 2020 15,8x
Yield 2020 5,08%
Sales 2021 36 230 M 47 280 M 47 280 M
Net income 2021 4 381 M 5 718 M 5 718 M
Net Debt 2021 21 205 M 27 672 M 27 672 M
P/E ratio 2021 17,8x
Yield 2021 5,08%
Capitalization 78 435 M 103 B 102 B
EV / Sales 2020 2,89x
EV / Sales 2021 2,75x
Nbr of Employees 99 437
Free-Float 91,2%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (52%): intended for respiratory diseases (67.5% of net sales), HIV infection (27.7%), immune system disorders (3.5%) ) and cancer (1,3%); - OTC and parapharmaceutical medicine (26.7%); - vaccines (21.2%); - other (0.1%). Net sales are distributed geographically as... 
More about the company
Surperformance© ratings of GlaxoSmithKline plc
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PLC
05:05pVir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
RE
08/10GLAXOSMITHKLINE : CureVac Sets IPO at 13.3 Million Shares; Sees Pricing at $14-$..
DJ
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
RE
08/10Biotech company CureVac aims to raise up to $245 mln in U.S. IPO
RE
08/07GLAXOSMITHKLINE : FDA approves GSK's BLENREP for the treatment of patients with ..
AQ
08/06GLAXOSMITHKLINE : FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the..
AQ
08/05GLAXOSMITHKLINE : U.S. FDA approves GlaxoSmithKline's blood cancer drug
RE
08/05GLAXOSMITHKLINE : FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the..
PU
08/03FOCUS : Next big COVID-19 treatment may be manufactured antibodies
RE
08/03Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
08/03GlaxoSmithKline and Sanofi to Supply EU With 300 Million Covid-19 Doses
DJ
08/01WHAT'S NEWS : World-Wide -- WSJ
DJ
07/31EU in talks to secure Sanofi deal for coronavirus vaccine
RE
07/31U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
RE
More news
News in other languages on GLAXOSMITHKLINE PLC
05:05pVir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in Au..
05:39aBAYER : sichert sich mögliches Blockbuster-Medikament
08/10GLAXOSMITHKLINE : CureVac Sets IPO at 13.3 Million Shares; Sees Pricing at $14-$..
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
08/10Biotech company CureVac aims to raise up to $245 million in U.S. IPO
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 872,93 GBX
Last Close Price 1 576,00 GBX
Spread / Highest target 42,1%
Spread / Average Target 18,8%
Spread / Lowest Target -2,47%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC-12.69%101 116
JOHNSON & JOHNSON1.87%389 737
ROCHE HOLDING AG-0.11%293 027
PFIZER, INC.-2.02%213 329
MERCK & CO., INC.-11.04%204 641
NOVARTIS AG-17.86%181 730